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Objectives: Regulatory policies, including economic incentivization through pat-
ent extensions, have been implemented to stimulate pediatric research, however 
disparity exists for the neonatal subpopulation. This analysis was conducted to 
identify the availability of neonate-specific data for frequently used medications in 
Neonatal Intensive Care Units (NICUs) and to determine the extent to which pedi-
atric exclusivity has increased information for drugs used in neonates. MethOds: 
A search was conducted utilizing the FDALabels database to identify all FDA-
approved NDA, BLA and ANDAs from 01/01/1980 to 08/01/2013 searching for the 
terms “neonate”, “newborn” and “infant” present in any of the following label sec-
tions; “Indication and Usage”, “Dosage and Administration” and “Pediatric Use”. 
The results were cross-referenced with a recently published list of 100 frequently 
prescribed drugs in NICUs and drugs granted pediatric exclusivity by the FDA as 
of August, 2013. Results: A total of 737 unique labels for 110 distinct drugs were 
identified (including 18 combination products and 15 modified versions of previ-
ously marketed drugs). “Newborn” was identified in 450 labels; “infant” in 414 labels 
and “neonate” in 167 labels. More than one search term was found in 294 labels. Only 
19% of drugs frequently used in NICUs mentioned neonates, newborns or infants on 
their labels. Mention of neonates, newborns or infants occurred in 4.5% (n= 9) of the 
drugs with pediatric exclusivity; while 8.7% (n= 17) of drugs granted pediatric exclu-
sivity were used frequently in the NICU. Only two drugs frequently used in NICUs 
mentioned neonate, newborn or infant on their label and had pediatric exclusiv-
ity. cOnclusiOns: Despite regulatory incentives, a paucity of neonatal data exist 
for drugs frequently used in NICUs. Our data suggest that pediatric exclusivity did 
not yield sufficient neonatal data.
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Objectives: One provision of the Patient Protection and Affordable Care Act (PPACA) 
requires that most insurers make prescription contraceptives—including refillable 
and long-acting reversible contraceptive methods (LARCs)—available at no out-
of-pocket cost to beneficiaries. The objective of this study was to determine if the 
implementation of the mandate increased contraceptive utilization. MethOds: 
We conducted a retrospective analysis using integrated pharmacy and medical 
claims for three cohorts of commercially-insured females aged 15 to 49. Each cohort 
(n= 360143, n= 352,169, and n= 391,138) was continuously enrolled for 12-month 
periods, respectively. “Pre-PPACA-Period 1” (January 1, 2011 to June 30, 2011) con-
sidered cost and utilization two years prior to PPACA. “Pre-PPACA-Period 2” (January 
1, 2012 to June 30, 2012) looked at the year prior to PPACA implementation, and the 
“Post-PPACA Period” (January 1, 2013 to June 30, 2013) captured the early experience 
immediately after implementation of the coverage mandate. Two pre-PPACA-periods 
allowed for better understanding of underlying secular trends occurring prior to 
the mandate. The incidence of new refillable and LARC methods, discontinuation 
and switching patterns and cost were measured across each time period. Results: 
The incidence of refillable contraceptive use increased minimally: from 3.45% in 
the first half of 2011 to 3.59% in the first half of 2012, and to 3.72% in the first half 
of 2013. The incidence of LARC use increased substantially (44.4% from 0.50% to 
0.65% between the first half of 2011 and the first half of 2013). The initiation rate 
of LARCs was significantly higher after the mandate compared to previous periods 
(OR= 1.45, 95% CI = 1.36-1.54), possibly due to increased switching from refillable to 
LARC methods. cOnclusiOns: We found little evidence that the PPACA contracep-
tive coverage mandate rule has yet resulted in meaningful increases in refillable 
contraceptive use, but it was associated with an increase in the initiation of LARCs.
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Objectives: To study the rationale of early prescription of antibiotics in case of 
patients with Organophosphorus poisoning. MethOds: In this study patients 
admitted to the ICU due to organophosphorus poisoning during a six-month 
period were included. Patients were grouped into group-A and group-B on the 
basis of antibiotics prescribed and not prescribed respectively.  The prescription of 
antibiotics was classified as prophylactic, empirical and definitive depending on 
the time of prescription. The effect of antibiotic prescription on the length of stay, 
cost and clinical outcome was observed. The cost of treatment was obtained from 
the finance department of the hospital. The length of stay and cost of treatment 
for the two groups were compared using the non-parametric Mann-Whitney U 
test. Results: There were 54 patients categorized in three groups according to the 
severity of poisoning as mild (22%), moderate (48%) and severe (30%). Antibiotics 
were prescribed for 74.07% of the patients. Prophylactic antibiotics were prescribed 
in 53.7% cases. The median cost of treatment for group-A patients was INR 60,216 
and for group-B patients was INR 27,225 (p= 0.001). The median length of stay 
for group-A and group-B was 14 days and 10 days respectively (p= 0.011). The 
median cost of treatment for moderately poisoned patients prescribed with pro-
phylactic antibiotics was INR 74595.6 as compared to INR 30,902 for moderately 
poisoned patients of group-B (p< 0.05). cOnclusiOns: Early prescription of anti-
biotics without any evidence of infection in case of organophosphorus poisoning 
patients showed a higher cost of treatment and inferior outcomes as compared 
to OPP cases where a prophylactic antibiotic was not prescribed. The use of higher 
antibiotics in these cases also lead to increase in antibiotic resistance. There is a 
need to revise the antibiotic prescription guidelines in case of Organophosphorus 
poisoning patients.
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Objectives: Use of potentially inappropriate medications (PIMs) among the elderly 
is a serious public health problem because it is intrinsically linked to increased 
morbidity and mortality, causing the high costs to public health systems. Objectives 
of this study were to determine the prevalence and predictors of PIM prescribing 
in elderly inpatients using STOP and START criteria MethOds: The prospective 
observational study was carried at a private tertiary care hospital. Prescriptions 
of elderly inpatients aged 60 years and above were collected and analyzed. PIMs 
were identified with the help of STOP and START criteria. Predictors associated 
with use of PIMs were identified by bivariate and multivariate logistic regression 
analysis. Results: The results were based on data of 60 patients. More than half 
(56%) were males and 50% were aged between 60–69 years with a mean average 
age of 69 years. Mean number of diagnoses and medications were two and nine, 
respectively. A total of 18 (30%) patients were prescribed with at least 1 PIM according 
STOP Criteria. Most commonly prescribed PIMs were systemic corticosteroids (29%) 
followed by theophyline (18%) and betablockers (10%). On multivariate regression, 
important predictors for PIM prescribing were found to polypharmacy, number of 
diagnoses. cOnclusiOns: The results show that PIMs prescribing is high in Indian 
elderly inpatients STOP and START criteria, it is more effective in identifying the 
PIMs. This study is ongoing and we will present the data upto 250 patents before 
the presentation.
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Objectives: To evaluate fracture-related expenses and health care resource utiliza-
tion among post-menopausal women in the U.S. Medicaid population. MethOds: 
Female patients diagnosed with fractures (International Classification of Disease, 
9th Revision, Clinical Modification [ICD-9-CM] codes: 733.12-.16, 805.0, 805.2, 805.4, 
805.6, 805.8, 808.0, 808.4, 808.8, 810.0, 812.0, 812.2, 812.4, 813.0, 813.2, 813.4, 813.8, 
814.0, 820.0, 820.2, 820.8, 821.0, 821.2, 823.0, 823.2, 823.4, 823.8) were identified using 
U.S. Medicaid data from 01JAN2009 through 31DEC2009. The initial diagnosis date 
was designated as the index date. A control cohort that included patients without 
fractures of the same age, race, region and baseline Charlson Comorbidity Index 
score was created. The index date for the control cohort was randomly assigned to 
minimize selection bias. Patients in both cohorts were required to be age ≥ 50 years, 
with continuous medical and pharmacy benefits for 1-year pre- and post-index date. 
Propensity score matching (PSM) was used to compare health care costs and utiliza-
tions during the follow-up period. Results: Before matching (n= 80,516), fracture 
patients were more likely to be white (71.2% vs. 46.2%), reside in the South U.S. region 
(39.2% vs. 34.1%) and have chronic obstructive pulmonary disease (26.7% vs. 21.3%). 
After 1:1 PSM, a total of 22,089 patients with proportionate baseline characteristics 
were matched from each cohort. Patients in the fracture cohort had higher propor-
tions of inpatient stays (31.0% vs. 8.1%, p< 0.0001), emergency room (ER; 47.0% vs. 
15.4%, p< 0.0001), physician office (73.6% vs. 47.3%, p< 0.0001) and outpatient visits 
(98.9% vs. 71.6%, p< 0.0001). Higher health care resource utilizations translated to 
higher costs for post-menopausal fracture patients than for controls, including long-
term care ($9,191 vs. $7,212, p< 0.0001), physician office visit ($428 vs. $293, p< 0.0001) 
and total costs ($17,698 vs. $13,032, p< 0.0001). cOnclusiOns: Post-menopausal 
women with fractures had significant health care resource utilization and expenses 
compared to those without fractures.
PIH61
evalUatIOn Of tHe POtentIal ImPact Of drUg-gene InteractIOn rIsk 
(dgIr) On HealtH resOUrce UtIlIzatIOn (HrU)
Bress A1, Unni S1, Biltaji E1, Sass RS2, Mamiya T2, Ye X1, Yu B1, Biskupiak JE1, Brixner D1
1University of Utah, Salt Lake City, UT, USA, 2Genelex, Inc, Seattle, WA, USA
Objectives: To assess the relationship between DGIR and HRU in elderly patients 
to evaluate potential benefit from pharmacogenetic testing. MethOds: A ret-
rospective cohort of patients age ≥ 65 years was identified through Inovalon’s 
MORE2® registry with continuous enrollment, taking ≥ 3 prescription medications 
(July 1, 2012 - March 31, 2013) and on ≥ 1 drug metabolized by a polymorphic drug 
metabolizing enzyme. Patients were stratified into zero, low, medium, and high 
DGIR groups via a diagnostic test (Genelex Youscript®). Counts of HRU during 9 
months follow-up post index-date (date of first claim for ≥ 1 drugs with pharma-
cogenetic implications) included all-cause hospitalizations, emergency-room and 
clinic visits. Poisson regression was used to test the association between DGIR and 
HRU counts. The model was adjusted for age, gender, race, Charlson Comorbidity 
Index (CCI) and number of known drug-drug interactions. Results: A total of 
252,184 patients were included and the mean age was 74 ± 6 and 60% were female. 
The median DGIR score was 8.7% [IQR 2.3%-44%]. There were 59,559 (23.6%) with 
a DGIR score of zero, 82,224 (32.6%) with low risk (0-20%), 33,439 (13.3%) with 
medium risk (20-40%), and 76,962 (30.5%) with high risk (> 40%). Regression analy-
sis revealed that the low and medium DGIR groups were associated with a 9% 
(95%CI 8.4 to 9.7%, p < 0.0001), and 8% (95%CI 7.7 to 9.2%, p < 0.0001) increase 
in the rate of HRU, compared to zero risk. The high DGIR group was associated 
with a 5% (95%CI 4.2 to 5.3%, p < 0.0001) decrease in HRU, compared to zero-
risk. cOnclusiOns: Among elderly patients, low and medium DGIR groups were 
associated with increased rates of HRU. In contrast, high DGIR was associated with 
lower HRU rates. This may be explained by a time-dependent effect of changing 
DGIR as a result of medication changes over time.
